Hoodwilkerson9269

Through the use of scientometric methods, this article has mapped the knowledge landscape of migraine research over the past decade. By showing the overall status of the field, it provides a useful reference for future research.

Pain is the most feared and distressing symptom in palliative care. In advanced stages of cancer, its incidence is 70-80%. In Mozambique there is little published information concerning to the prevalence, intensity, and pain's management in cancer patients.

A cross-sectional observational study was conducted between August 2018 and January 2019, in Mozambique's main hospitals, and in the only hospital with an isolated provision of palliative care service. The analyzed data included demographic data, pain intensity and its treatment. The Pain Management Index was used to calculate the adequacy of the analgesia.

A total of 294 patients were included. The mean patients' age was 46.1 years old. Concerning to pain, 83.7% of the patients had pain, most of them moderate to severe pain. The prevalence of pain was frequent in women mainly in cervical cancer (84.3%) and in men with Kaposi sarcoma (80%). The main analgesic used for severe pain was paracetamol, and it was used alone in 40.9% of the patients. Morphine was used in 8.1% and adjuvants less than 10%. Pain Management Index was negative for 68.7% of the sample, meaning an inadequate analgesia. Significant differences were found in Pain Management Index levels between hospitals.

The prevalence of pain in the main health institutions in Mozambique is high. Paracetamol was the analgesic most used in severe pain. Further studies are needed to understand the main reasons of patients' suffering.

The prevalence of pain in the main health institutions in Mozambique is high. Paracetamol was the analgesic most used in severe pain. Further studies are needed to understand the main reasons of patients' suffering.

Adjuvant chemotherapy can cause neutropenia by inhibition of hematopoiesis. However, little information is known about the effects of chemotherapy-induced neutropenia (CIN) on the outcomes of direct-to-implant (DTI) immediate breast reconstruction after skin-sparing mastectomy.

A retrospective review was performed for all patients with DTI immediate breast reconstruction after skin-sparing mastectomy (n=372) between January 2011 and December 2019. The demographic and complication of patients who experienced CIN during chemotherapy and those who did not were compared.

Major infection requiring surgical management occurred in 4 patients (7.1%) in the CIN group (n=56) and 2 (3.6%) in the non-CIN group (n=55). Minor infection requiring antibiotics treatment occurred in 1 patient (1.8%) in the CIN group and 1 (1.8%) in the non-CIN group. Skin necrosis occurred in 7 patients (12.5%) in CIN group and 11 patients (19.6%) in non-CIN group. There were no significant difference in incidence of all complications between two groups.

CIN may not significantly increase the incidence of severe complications in the patients who received adjuvant chemotherapy after DTI immediate breast reconstruction. However, close observation is required for possible breast complication and adequate treatment is needed.

CIN may not significantly increase the incidence of severe complications in the patients who received adjuvant chemotherapy after DTI immediate breast reconstruction. However, close observation is required for possible breast complication and adequate treatment is needed.

This investigation systematically evaluated the selenium levels and the effects of selenium supplementation in patients with autoimmune thyroid disease (AITD).

Randomized controlled trials (RCTs) related to selenium supplementation in patients with AITD were selected from the PubMed, Medline, Web of Sciences, Embase, Cochrane Library, and Spring databases. All related literature published between January 2000 and November 2020 were included. The RCT bias risk assessment was conducted according to the Cochrane Handbook 5.0.2. The Review Manager 5.3 software was applied for meta-analysis of the included literature.

A total of 17 articles meeting the requirements were selected, including a total of 1,911 subjects. Meta-analysis results showed that the serum free triiodothyronine (FT3) levels in patients was greatly reduced after selenium supplementation compared to placebo treatment (MD =-0.40; 95% confidential interval (CI) -0.70--0.10; Z=2.61; P=0.009). Serum free thyroxine (FT4) levels and anti-thyroid selenium supplementation showed a very important effect on AITD.

Researchers have not clearly determined whether adding aprepitant (ADH) to dexamethasone and one 5-HT3 receptor antagonist (DH) is clinically effective at preventing chemotherapy-induced nausea and vomiting (CINV) among patients with lung cancer (LC) treated with platinum-based chemotherapy (PBC). Therefore, we conducted a meta-analysis to examine the efficacy and safety of ADH and DH.

We searched the PubMed, ScienceDirect, Cochrane Library, and Scopus databases, among others, for relevant studies. The primary outcomes were the complete response (CR) and the no nausea rate (NNR). The secondary endpoints were the number of patients who needed rescue antiemetic treatment (RAT), adverse events (AEs), and the Functional Living Index Emesis (FLIE) score.

We initially screened 2,118 articles; ultimately, four randomized controlled trials (RCTs) with 518 patients were included. The ADH group had a superior overall CR [risk ratio (RR) 1.16 (1.06, 1.27), P=0.002] and a lower number of patients who needed RAT [RR 0.44 (0.29, 0.65), P<0.0001]. Saracatinib The ADH group also had a better overall NNR [RR 1.11 (0.97, 1.26), P=0.12] and delayed CR [RR 1.12 (0.97, 1.31), P=0.13]. No significant differences were observed in acute CR, acute NNR, or delayed NNR. In the subgroup analysis of the overall CR and NNR, ADH was superior in certain clinical characteristics (China, cisplatin-based chemotherapy, 2nd-generation 5-HT3 receptor antagonist, ADC <50%, and Eastern Cooperative Oncology Group (ECOG) score of 0-2). No significant differences in the AEs characterized as hematological or nonhematological toxicity were observed between the groups.

Compared with DH, ADH appears to be superior at preventing CINV and achieving a better CR among patients with LC treated with PBC.

Compared with DH, ADH appears to be superior at preventing CINV and achieving a better CR among patients with LC treated with PBC.